KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EBITDA: 2009-2025

Historic EBITDA for Idexx Laboratories (IDXX) over the last 17 years, with Sep 2025 value amounting to $354.8 million.

  • Idexx Laboratories' EBITDA rose 16.77% to $354.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 17.46%. This contributed to the annual value of $1.1 billion for FY2024, which is 2.84% up from last year.
  • Idexx Laboratories' EBITDA amounted to $354.8 million in Q3 2025, which was down 4.88% from $373.0 million recorded in Q2 2025.
  • Idexx Laboratories' EBITDA's 5-year high stood at $373.0 million during Q2 2025, with a 5-year trough of $179.1 million in Q2 2022.
  • Over the past 3 years, Idexx Laboratories' median EBITDA value was $296.1 million (recorded in 2023), while the average stood at $297.3 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 71.57% in 2021, then slumped by 30.93% in 2022.
  • Quarterly analysis of 5 years shows Idexx Laboratories' EBITDA stood at $199.2 million in 2021, then climbed by 13.72% to $226.5 million in 2022, then increased by 8.29% to $245.3 million in 2023, then increased by 6.68% to $261.7 million in 2024, then increased by 16.77% to $354.8 million in 2025.
  • Its EBITDA was $354.8 million in Q3 2025, compared to $373.0 million in Q2 2025 and $316.5 million in Q1 2025.